Drug intelligence / Profile preview

ketamine + hydromorphone

Development stage
Phase 4
Lead developer
PharmaTher
Modality
Small Molecules
Administration
Intravenous, Intramuscular, Subcutaneous
01

Overview

Ketamine + hydromorphone is a combination of two analgesic agents used primarily for the management of moderate to severe pain, especially in perioperative and postoperative settings. Hydromorphone is a potent opioid agonist that acts mainly on mu-opioid receptors to provide analgesia by altering the perception and response to pain in the central nervous system. Ketamine is an N-methyl-D-aspartate (NMDA) receptor antagonist with dissociative anesthetic properties; it provides analgesia by inhibiting central sensitization and reducing opioid tolerance or hyperalgesia. The combination is often used as part of intravenous patient-controlled analgesia (IV-PCA) regimens, where ketamine serves as an adjuvant to reduce total opioid requirements, mitigate opioid-induced side effects such as pruritus, and potentially improve pain control without increasing adverse events[1][4][8]. This approach may be particularly beneficial for patients with high postoperative pain or those who are tolerant or resistant to opioids.

02

Targets

DOR (Opioid Receptor Delta 1)KOR (Kappa opioid receptor)MOR (Mu opioid receptor)NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on ketamine + hydromorphone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ketamine + hydromorphone.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call